Bank of America Lifts Eli Lilly Target to $1,251, Flags Chip Picks for AI 800V
BAC•Bank of America boosted its Eli Lilly price target to $1,251 from $1,133, citing rising demand for obesity and diabetes treatments. It also named Texas Instruments, Analog Devices and ON Semiconductor top analog chip picks, raising targets to $370 and $138 and forecasting AI-driven 800V gains.
1. Eli Lilly Price Target Revision
Bank of America raised its Eli Lilly price target from $1,133 to $1,251 and maintained a Buy rating. The firm highlighted expanding GLP-1 drug demand for obesity and diabetes as the key growth driver and noted the obesity pipeline could sustain revenue beyond the 2036 patent expiration.
2. Top Analog Semiconductor Picks
The firm identified Texas Instruments, Analog Devices and ON Semiconductor as its top analog semiconductor stocks. Price targets were increased on Texas Instruments to $370 and on ON Semiconductor to $138, with projections of a $4.5 billion data center business for Texas Instruments by 2028, $3.3 billion in AI sales at Analog Devices and $1.6 billion in AI-driven sales at ON Semiconductor.
3. Research Business Implications
These research calls underscore Bank of America’s focus on high-growth sectors, signaling confidence in pharmaceutical pipelines and AI-related semiconductor demand. Investors may view these updates as indicators of structural trends in GLP-1 adoption and next-generation data center architectures.
